290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers

In a phase 2A trial, brepocitinib, a TYK2/JAK1 inhibitor, demonstrated clinical improvement in patients with cicatricial alopecias (CA), including lichen planopilaris, frontal fibrosing alopecia, and central centrifugal cicatricial alopecia. The study involved 49 participants, randomized to receive either brepocitinib or a placebo for 24 weeks, followed by an open-label phase where all received brepocitinib. Significant downregulation of Th1, Th2, Th17/IL23, T-cell activation, Treg, and fibrosis biomarkers was observed in patients treated with brepocitinib, correlating with clinical improvements. No significant changes were noted in the placebo group, highlighting brepocitinib's potential as a treatment for CA.